Recent Advances in IRAK1: Pharmacological and Therapeutic Aspects

被引：10

作者：

Kim, Kyeong Min ^{[1
]}

Hwang, Na-Hee ^{[1
]}

Hyun, Ja-Shil ^{[1
]}

Shin, Dongyun ^{[1
]}

机构：

[1] Gachon Univ, Coll Pharm, Hambakmoe Ro 191, Incheon 21935, South Korea

来源：

MOLECULES | 2024年 / 29卷 / 10期

基金：

新加坡国家研究基金会;

关键词：

interleukin receptor-associated kinase (IRAK) proteins; inhibitor; degrader; immunity; SIGNALING MEDIATOR; KINASE IRAK; INNATE; ACTIVATION; INFLAMMATION; INHIBITORS; FAMILY; NEUROINFLAMMATION; IDENTIFICATION; MICRORNA-146A;

D O I：

10.3390/molecules29102226

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Interleukin receptor-associated kinase (IRAK) proteins are pivotal in interleukin-1 and Toll-like receptor-mediated signaling pathways. They play essential roles in innate immunity and inflammation. This review analyzes and discusses the physiological functions of IRAK1 and its associated diseases. IRAK1 is involved in a wide range of diseases such as dry eye, which highlights its potential as a therapeutic target under various conditions. Various IRAK1 inhibitors, including Pacritinib and Rosoxacin, show therapeutic potential against malignancies and inflammatory diseases. The covalent IRAK1 inhibitor JH-X-119-01 shows promise in B-cell lymphomas, emphasizing the significance of covalent bonds in its activity. Additionally, the emergence of selective IRAK1 degraders, such as JNJ-101, provides a novel strategy by targeting the scaffolding function of IRAK1. Thus, the evolving landscape of IRAK1-targeted approaches provides promising avenues for increasingly safe and effective therapeutic interventions for various diseases.

引用

页数：17

共 100 条

[51] IRAK4 in TLR/IL-1R signaling: Possible clinical applications [J].

Li, Xiaoxia .

EUROPEAN JOURNAL OF IMMUNOLOGY, 2008, 38 (03) :614-618

[52]

Li XX, 1999, MOL CELL BIOL, V19, P4643

[53] miR-146a Enhances the Sensitivity of Breast Cancer Cells to Paclitaxel by Downregulating IRAK1 [J].

Li, Yalun ;

Li, Weilong ;

Lin, Jun ;

Lv, Chunjing ;

Qiao, Guangdong .

CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2022, 37 (08) :624-635

[54] Targeting the Innate Immune Kinase IRAK1 in Radioresistant Cancer: Double-Edged Sword or One-Two Punch? [J].

Liu, Peter H. ;

Sidi, Samuel .

FRONTIERS IN ONCOLOGY, 2019, 9

[55] BAP31 regulates IRAK1-dependent neuroinflammation in microglia [J].

Liu, Xia ;

Jiao, Kun ;

Jia, Cong-cong ;

Li, Guo-xun ;

Yuan, Qing ;

Xu, Ji-kai ;

Hou, Yue ;

Wang, Bing .

JOURNAL OF NEUROINFLAMMATION, 2019, 16 (01)

[56] miR-146a-5p targets interleukin-1 receptor-associated kinase 1 to inhibit the growth, migration, and invasion of breast cancer cells [J].

Long, Jing-Pei ;

Dong, Li-Feng ;

Chen, Fang-Fang ;

Fan, Yang-Fan .

ONCOLOGY LETTERS, 2019, 17 (02) :1573-1580

[57] 1,4-Naphthoquinone Is a Potent Inhibitor of IRAK1 Kinases and the Production of Inflammatory Cytokines in THP-1 Differentiated Macrophages [J].

Mahmoud, Ismail Sami ;

Hatmal, Ma'mon M. ;

Abuarqoub, Duaa ;

Esawi, Ezaldeen ;

Zalloum, Hiba ;

Wehaibi, Suha ;

Nsairat, Hamdi ;

Alshaer, Walhan .

ACS OMEGA, 2021, 6 (39) :25299-25310

[58] Microglia and Inflammation in Alzheimer's Disease [J].

Mandrekar-Colucci, Shweta ;

Landreth, Gary E. .

CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2010, 9 (02) :156-167

[59] Biological drivers of clinical phenotype in myelofibrosis [J].

Mascarenhas, John ;

Gleitz, Helene F. E. ;

Chifotides, Helen T. ;

Harrison, Claire N. ;

Verstovsek, Srdan ;

Vannucchi, Alessandro Maria ;

Rampal, Raajit K. ;

Kiladjian, Jean-Jacques ;

Vainchenker, William ;

Hoffman, Ronald ;

Schneider, Rebekka K. ;

List, Alan F. .

LEUKEMIA, 2023, 37 (02) :255-264

[60] Pacritinib for the treatment of patients with myelofibrosis and thrombocytopenia [J].

Mascarenhas, John .

EXPERT REVIEW OF HEMATOLOGY, 2022, 15 (08) :671-684

← 1 2 3 4 5 6 7 8 9 10 →